Myelofibrosis with Myeloid Metaplasia: New Developments in Pathogenesis and Treatment

DOI Web Site Web Site PubMed 被引用文献1件 参考文献139件
  • DINGLI David
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine
  • MESA Ruben A.
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine
  • TEFFERI Ayalew
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine

この論文をさがす

抄録

Myeloid metaplasia with myelofibrosis (MMM) is a chronic myeloproliferative disorder (CMPD) characterized by progressive anemia, massive splenomegaly, both hepatosplenic and non-hepatosplenic extramedullary hematopoiesis (EMH), a leukoerythroblastic blood smear, circulating progenitor cells, and marked bone marrow stromal reaction including collagen fibrosis, osteosclerosis and angiogenesis. The overall median survival is 5 years although it might range from 2 to 15 years depending on the presence or absence of clinically defined prognostic factors. Death is often due to leukemic transformation, portal hypertension or infection. In addition to shortened survival, quality of life is often affected by frequent red blood cell transfusions, profound constitutional symptoms, and cachexia. Drug therapy and autologous hematopoietic stem cell transplantation (HSCT) are of only palliative value and have not been shown to improve survival. The role of allogeneic HSCT, both myeloablative and non-myeloablative, is actively being investigated. Both splenectomy and radiation therapy have defined therapeutic roles to control EMH-associated symptoms. Analysis of the molecular biology of the disease is underway with the aid of animal models leading to the identification of novel therapeutic targets. Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon.

収録刊行物

  • Internal Medicine

    Internal Medicine 43 (7), 540-547, 2004

    一般社団法人 日本内科学会

被引用文献 (1)*注記

もっと見る

参考文献 (139)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ